Phase II study of oral APL-1202 plus tislelizumab or tislelizumab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC).

Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Xiaoliang Yuan(Jiangsu University), Hailong Hu(Second Hospital of Tianjin Medical University), Badrinath R. Konety(Allina Health), Xiaodong Song(Binzhou Medical University), Dalin He(Sichuan University), Dingwei Ye(Fudan University Shanghai Cancer Center), John P. Sfakianos(Mount Sinai Medical Center), Gongxian Wang(Nanchang University), Hanzhong Li(Chinese Academy of Medical Sciences & Peking Union Medical College)
Journal of Clinical Oncology
February 10, 2025
10.1200/jco.2025.43.5_suppl.793
Cited by 1

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786